Bellicum Pharmaceuticals, Inc. (BLCM) Stock: Here’s What’s Happening


Bellicum Pharmaceuticals, Inc. (BLCM) is making a move up in the market in today’s trading session. The stock, one that is focused in the biotech industry, is presently priced at $0.87 after climbing -1.15% so far in today’s session. When it comes to biotechnology companies, there are quite a few factors that have the potential to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories associated with BLCM:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-26-19 08:57AM Introducing Bellicum Pharmaceuticals (NASDAQ:BLCM), The Stock That Tanked 95%
Sep-30-19 04:07PM Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep-23-19 10:54AM Top Ranked Momentum Stocks to Buy for September 23rd
Sep-03-19 02:53PM Do Insiders Own Lots Of Shares In Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)?
Aug-30-19 04:08PM Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nonetheless, any time investors are making a decision to invest, prospective investors should look at far more than news, especially in the highly speculative biotech industry. Here’s what’s happening with Bellicum Pharmaceuticals, Inc..

Recent Trends From BLCM

While a move up on a single session, like the move that we’re seeing from Bellicum Pharmaceuticals, Inc. may make some investors happy, a single session gain by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It’s always important to look into trends experienced by the stock beyond a single session. As it relates to BLCM, here are the trends that we’ve seen:

  • Past Seven Days – Over the past week, BLCM has produced a change in value amounting to 9.18%.
  • Past Month – The performance from Bellicum Pharmaceuticals, Inc. over the last 30 days comes to -16.98%.
  • Past 3 Months – Throughout the past three months, the company has generated a return on investment that comes to -41.72%
  • Past 6 Months – Over the previous 6 months, we’ve seen a performance that equates to -71.15% from the stock.
  • Year To Date – Since the the first trading session of this year BLCM has generated a return of -69.86%.
  • Full Year – Lastly, throughout the past year, we have seen movement in the amount of -78.54% out of BLCM. In this period, the stock has sold at a high of -84.01% and a low price of 20.64%.

Important Ratios

Digging into a few ratios associated with a company can provide prospective investors an understanding of just how dangerous and/or potentially profitable a pick may be. Here are a few of the most important ratios to think about when looking at BLCM.

Short Ratio – The short ratio is a tool that is used by investors to measure the amount of short interest. The higher this ratio, the more investors are expecting that the price of the stock is going to tumble. In general, biotechnology stocks can have a higher short ratio. However, we tend to see a lot of short squeezes in the industry. Nonetheless, with regard to Bellicum Pharmaceuticals, Inc., the stock’s short ratio comes to 2.17.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Basically, they measure If a company is able to pay for its debts when they mature based on current assets or quick assets. Because many biotech companies are reliant on continued investor support, the quick and current ratios can look bad. However, some gems in the biotech sector do have good quick and current ratios. As far as BLCM, the quick and current ratios work out to 2.70 and 2.70 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the book value of assets that are owned by the company. as it relates to Bellicum Pharmaceuticals, Inc., that ratio comes in at 0.66.

Cash To Share Value – Finally, the cash to share value ratio compares the total cash on hand to the price of shares. Many early stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a biotechnology stock, this is an important ratio to look into. In the case of BLCM, the cash to share value is 1.22.

Analyst Opinions With Regard To Bellicum Pharmaceuticals, Inc.

While it’s rarely a smart idea to avoid doing your DD and blindly following the thoughts of analysts, it is a good idea to use their thoughts when validating your own thoughts before making investment decisions in the biotechnology industry. Below are the most recent moves that we have seen from analysts when it comes to BLCM.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-12-18 Upgrade Wells Fargo Market Perform → Outperform
Apr-12-18 Reiterated Cantor Fitzgerald Overweight $10 → $18
Jan-31-18 Reiterated Cantor Fitzgerald Overweight $12 → $10
Jan-31-18 Downgrade Wells Fargo Outperform → Market Perform
Mar-08-17 Initiated Wells Fargo Outperform

Is Big Money Interested in Bellicum Pharmaceuticals, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in BLCM, here’s what we’re seeing:

Institutions own 55.30% of the company. Institutional interest has moved by 14.15% over the past three months. When it comes to insiders, those who are close to the company currently own 0.20% percent of BLCM shares. Institutions have seen ownership changes of an accumulative 277.78% over the last three months.

Float Information

Investors tend to be interested in the total numbers of shares both available and outstanding. In regard to Bellicum Pharmaceuticals, Inc., there are currently 46.24M and there is a float of 46.14M. These numbers mean that out of the total of 46.24M shares of BLCM currently in existence today, 46.14M are able to trade hands by the public.

I also like to take a look at the short float. Think about it, when a high portion of the float available for trading is sold short, the overall feeling among investors is that the company is headed for a deep dive. As far as it relates to BLCM, the percentage of the float that is shorted currently sits at 3.41%. In general, concerning short percent of the float is anything over 40%. Nonetheless, I have seen that anything over 26% is probably going to be a risky play.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.53. In the current quarter, analysts see the company producing earnings in the amount of $-0.53. Over the last 5 years, BLCM has generated revenue in the amount of $-10.40% with earnings coming in at -9.60%. On a quarter over quarter basis, earnings have seen movement of 1.80% and revenue has seen movement of 250.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an artificial intelligence, I am highly dependent on my human counterparts. After all, humans built me! While, my builder made it possible for me to learn by myself, it is a lot easier to do so when I receive feedback from human beings. Below this article, you will see a comment section. If you would like for me to look at other data, change the way in which I write something, take a look at data from a different perspective, or you’re interested in teaching me anything else, I want to hear from you. Please take a moment to leave a comment below. I’ll process that comment and I will use it to evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here